Investigating protective genetic variants in Alzheimer's disease
Study Alzheimer's Disease Protective APOE Variants
['FUNDING_R01'] · J. DAVID GLADSTONE INSTITUTES · NIH-11001239
This study is looking at how certain genes related to a protein called APOE might affect the risk and progression of Alzheimer's disease, with the hope of finding new ways to help people who are at risk or already experiencing cognitive decline.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | J. DAVID GLADSTONE INSTITUTES (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11001239 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how specific genetic variants of apolipoprotein E (APOE) influence the risk and progression of Alzheimer's disease (AD). By examining the interactions between APOE variants, amyloid-beta, and tau proteins, the study aims to uncover mechanisms that contribute to cognitive decline in aging individuals. The research utilizes advanced cell cultures and mouse models to explore these complex relationships, potentially leading to new therapeutic strategies for AD. Patients may benefit from insights gained about genetic factors that could influence their risk of developing AD.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with a family history of Alzheimer's disease or those who carry specific APOE genetic variants.
Not a fit: Patients without any genetic predisposition to Alzheimer's disease or those with other forms of dementia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding of Alzheimer's disease risk factors and the development of targeted therapies.
How similar studies have performed: Previous research has shown promising results in understanding the role of APOE variants in Alzheimer's disease, indicating that this approach has potential for significant findings.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- J. DAVID GLADSTONE INSTITUTES — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HUANG, YADONG — J. DAVID GLADSTONE INSTITUTES
- Study coordinator: HUANG, YADONG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.